

Expression And Biological Interaction Network Of RHOC For Hepatic Carcinoma With Metastasis In PBMC Samples

This article was published in the following Dove Press journal:
OncoTargets and Therapy

Yanting Shen¹
Lu Bu²
Rui Li³
Zhenzhu Chen³
Fei Tian³
Qinyu Ge³ 

¹Department of Science and Education, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai 201700, People's Republic of China;

²Department of Interventional Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, People's Republic of China; ³State Key Laboratory of Bioelectronics, Southeast University, Nanjing 210096, People's Republic of China

Objectives: Hepatic carcinoma with metastasis remains incurable, and clinical diagnostic methods lacked adequate sensitivity and specificity. Therefore, seeking effectively diagnostic biomarkers is still essential for it. *RHOC* was reported to be linked to metastasis of hepatic carcinoma. However, almost all of the studies used tissues as detection samples, which was not ideal for clinical course minoring. Therefore, here, it was aimed to use PBMC samples that were not only easily accessible but also minimally invasive to determine the expression and biological interaction network of *RHOC* for hepatic carcinoma with metastasis.

Methods: PBMC samples were isolated. Then, RNA-seq was performed to identify the DEGs between hepatic carcinoma with metastasis and hepatic carcinoma with solitary tumor. Subsequently, q-RT-PCR was used to verify the expression level of *RHOC*. Finally, bioinformatic analysis was used to present the biological interaction network of *RHOC* for hepatic carcinoma with metastasis in PBMC samples.

Results: The results of both RNA-seq and q-RT-PCR showed that the expression level of *RHOC* was significantly higher in the PBMC samples of hepatic carcinoma with metastasis than in those of hepatic carcinoma with solitary tumor. By using variety of bioinformatic analysis platforms, in PBMCs, 18 co-expression genes with *RHOC* were identified and their interaction network showed that *MYL9* and *RHOC* had the highest edge evidence, and were involved in some cell migration-related pathways.

Conclusion: Our results indicated that *RHOC* in PBMCs could be potentially minimally invasive indicators for the diagnosis and clinical course supervision of hepatic carcinoma with metastasis, and its biological interaction network determined based on bioinformatic methods would lay a foundation for further study of the role of *RHOC* in tumor invasion and metastasis.

Keywords: *RHOC*, hepatic carcinoma, metastasis, PBMC, diagnosis

Introduction

Hepatic carcinoma is the third leading cause among all of the cancer-related deaths globally.¹ Although its morbidity and mortality have decreased recently due to some related advances in cancer diagnosis and treatment, majority of the patients remains incurable with an unsatisfactory long-term prognosis once their tumor have become metastatic.²⁻⁴ The existing imaging diagnosis and serum biomarkers detection are highly used for hepatic carcinoma. However, the typically sensitive and specific diagnostic method for the hepatic carcinoma with metastasis are still lacking, especially for the small metastasis or micro-metastasis. Thus, it is essential to explore new effectively diagnostic markers.

Correspondence: Qinyu Ge
State Key Laboratory of Bioelectronics,
Southeast University, Sipailou Road No. 2,
Nanjing, Jiangsu Province 210096, People's
Republic of China
Tel +86 25 8379 3779
Email geqinyu@seu.edu.cn

Recently, it has been generally accepted that the diversity of biological characteristics determines the invasive and metastatic potentials of hepatic carcinoma, especially for the alteration of gene expression underlying this process.^{5,6} Therefore, growing attentions are paid on the analysis of differentially expressed genes (DEGs). Available information indicates that invasion and metastasis is to a large extent attributable to the ability of cell migration.^{7,8} Ras homolog family member C (RHOC), a member of the Ras superfamily of small guanosine triphosphatases (GTPases), was regarded as a key molecular which was involved in the process of cell migration.⁹ Increasing evidence presented that up-regulated expression level of *RHOC* has been significantly linked to increased invasion and metastasis of hepatic carcinoma.^{10–16} Besides the RHOC mediate Rho/ROCK signaling pathway which was involved in the process of cell migration,¹⁷ some other biological pathways were also reported to play a role in the hepatic carcinoma with metastasis, such as transforming growth factor- β 1 (TGF- β 1) induced signaling pathway,¹³ autocrine motility factor signaling pathway,¹⁴ and vascular endothelial growth factor (VEGF) induced angiogenesis signaling pathway.¹⁸ It indicated that there was a complex gene regulation network of *RHOC*, being significantly linked to the hepatic carcinoma with metastasis.

In order to shed light on these points above, RNA-seq was performed to delineate the profile of DEGs between hepatic carcinoma with metastasis and hepatic carcinoma with solitary tumor in peripheral blood mononuclear cell (PBMC) samples. It was worth noting that PBMC samples had two advantages when compared to the hepatic carcinoma tissues which were used as the main detection sample type in almost all published related studies.^{10–16} The first one was that its component was simple. It would decrease the intra-tumor heterogeneity, making the result more reliable and consistent.¹⁹ The second one was that PBMC was not only easily accessible but also minimally invasive, so that it was the ideal detection sample for monitoring tumor progression. Our results showed that through RNA-seq, 469 DEGs between hepatic carcinoma with metastasis and hepatic carcinoma with solitary tumor in PBMC samples were identified. Then, *RHOC*, which was dysregulated in the tissue samples of hepatic carcinoma^{10–16} and had a potential association with tumor metastasis, was selected for further validation by using q-RT-PCR. In addition, the gene regulation network of *RHOC* linked to hepatic carcinoma with metastasis in PBMC were also drawn by using multi-dimensional bio-

informatic analysis methods. Thus, to our knowledge, our results firstly revealed that *RHOC* in PBMC samples had a potential to be a new easily accessible and minimally invasive diagnostic and minor bio-marker for hepatic carcinoma with metastasis.

Methods And Materials

Patients

Thirty-three blood samples were collected from patients who visited Zhongda Hospital Affiliated Southeast University (Nanjing, China). Among them, 15 samples were collected from the patients who were diagnosed as hepatic carcinoma with solitary tumor; 18 samples were collected from the patients who were diagnosed as hepatic carcinoma with metastasis. All of them did not receive any treatment and wrote informed consents. This study got ethics approval from the Ethics Committee of Zhongda Hospital Affiliated Southeast University and was conducted in accordance with the Declaration of Helsinki. In this study, the hepatic carcinoma with single node and without intrahepatic or extrahepatic metastasis was defined as a solitary tumor, the hepatic carcinoma with intrahepatic or extrahepatic metastasis was defined as hepatic carcinoma with metastasis.

PBMC Isolating And RNA Extraction

Ficoll-PaqueTM PREMIUM was used to isolate PBMCs, and TRIZOL (Invitrogen, Carlsbad, CA) was used to extract RNA.^{19,41} RNA quality was accessed using NanoDrop ND-1000 (Thermo Fisher Scientific, Waltham, MA), and its integrity was determined by RNA integrity number (RIN; Agilent 2100 RIN Beta Version Software).

RNA-Seq And Bio-Informatic Analysis

Twenty-three samples (13 samples of hepatic carcinomas with metastasis were regarded as the cases, and 10 samples of hepatic carcinomas with solitary tumor were regarded as the controls) were chosen for RNA-seq. Their clinical information was showed in our previous study.¹⁹ The preparation of poly-(A) enriched RNA sequencing libraries and the procedures of filtering, mapping, alignment, and DEGs analysis were described in our previous study.¹⁹ The P -value ≤ 0.05 and an absolute value of $\log_2 FC > 2$ were treated as the thresholds to judge the significance of DEGs.

For the gene expression network analysis, PANTHER (protein annotation through evolutionary relationship) classification system (<http://www.pantherdb.org/>) were used to

perform GO and pathway classification analysis.⁴² STRING v 11.0 (<http://string-db.org/cgi/input.pl>) was used for constructing PPI network and performing Reactome pathway enrichment analysis.⁴³ cBio Cancer Genomics Portal (<http://cbioportal.org>), an open-access resource for interactive exploration of multidimensional cancer genomics data sets, currently containing 225 cancer studies,⁴⁴ was used to analyze the types and frequency of gene alterations and biological interaction network with neighboring genes in this study. The LinkFinder module of LinkedOmics database (<http://www.linkedomics.org/login.php>), a web-based platform for analyzing 32 TCGA cancer-associated multi-dimensional datasets, was used to select the co-expression genes of *RHOC* in TCGA database.⁴⁵ StarBase (<http://starbase.sysu.edu.cn/>) is designed for decoding the interaction networks of lncRNAs, miRNAs, ceRNAs, RNA-binding proteins (RBPs) and mRNAs supported by multi-dimensional sequencing data, including cross-linking immunoprecipitation (CLIP)-seq, degradome-seq and RNA-RNA interactome data.^{46,47} StarBase v3.0 was updated in 2018. It identified more than 1.1 million miRNA-ncRNA, 2.5 million miRNA-mRNA, 2.1 million RBP-RNA, and 1.5 million RNA-RNA interactions. And its Pan-Cancer Analysis Platform is designed for decoding Pan-Cancer Networks of lncRNAs, miRNAs, pseudogenes, snoRNAs, RBPs and all protein-coding genes by analyzing their expression profiles across 32 cancer types (~10,000 RNA-seq and ~9,900 miRNA-seq samples) integrated from TCGA project. In this study, the RNA-ceRNA module and RNA-RNA module of StarBase v3.0 were used to confirm the co-expression genes with *RHOC* in TCGA database. Pan-Cancer module was used to analyze overall survival for LIHC. When the FDR or P-value was less than 0.05, the result was significant.

q-RT-PCR

Ten PBMC samples (5 hepatic carcinomas with metastasis were regarded as the cases, and 5 hepatic carcinomas with solitary tumor were regarded as the controls) were used for qRT-PCR. The primers were synthesized by Takara Bio, Inc and showed in Table 1. The procedure of q-RT-PCR was the same as that was previously reported.¹⁹ Two percent agarose gel electrophoresis and dissociation curve were used to access the quality of its amplification products (Figures S3 and S4).

Statistical Analysis

The data were analyzed with MATLAB[®] (version 2010b). Statistical differences were examined by a *t*-test. The

Table 1 Sequences Of Primers

Name Of Primers	Sequences (5' To 3')
<i>RHOC</i>	Forward: GGAGGTCTACGTCCCTACTGT Reverse: CGCAGTCGATCATAGTCTTCC
<i>ACTB</i>	Forward: CATGTACGTTGCTATCCAGGC Reverse: CTCCTAATGTACACGACGAT

relationship between the expression level of *RHOC* and T staging was analyzed by Spearman test. When P-values were less than 0.05, it was regarded as significant.

Results

DEGs Profiling For Hepatic Carcinoma With Metastasis Vs Hepatic Carcinoma With Solitary Tumor In PBMC Samples

Through RNA-seq, 469 DEGs were identified in PBMC samples of hepatic carcinoma with metastasis and hepatic carcinoma with solitary tumor. Among them, 352 DEGs were up-regulated, and 117 DEGs were down-regulated (Figure 1 and Table S1). Their functional classification was performed by PANTHER Classification System. As Figure 2 shown, these DEGs were the main component of cell (gene ontology (GO): 0005623), organelle (GO: 0043226), extra-cellular region (GO: 0005576), membrane (GO: 0016020), and protein-containing complex (GO: 0032991). They played a role in cellular process (GO: 0009987), such as binding (GO: 0005488), catalytic




Figure 1 Volcano plot of DEGs identified in PBMC samples for hepatic carcinoma with metastasis vs hepatic carcinoma with solitary tumor.

Notes: 469 DEGs were identified by RNA-seq. Among them, 352 genes were up-regulated, and 117 genes were down-regulated.




Figure 3 PPI network of DEGs for hepatic carcinoma with metastasis in PBMC samples (STRING).

Notes: Number of nodes: 454; number of edges: 1362; average node degree: 6; Avg. local clustering coefficient: 0.398; expected number of edges: 728; PPI enrichment P-value: $<1.0E-16$. Thicker line indicates increased edge confidence.

Validation Of *RHOC* By q-RT-PCR

In order to further validate the expression of *RHOC*, another 10 PBMC samples were collected and used to perform q-RT-qPCR. Their baseline characteristics are shown in Table 2. The result showed that *RHOC* was significantly higher in PBMC samples of hepatic carcinoma with metastasis than in those of hepatic carcinoma with solitary tumor (7.15 ± 0.88 vs 8.66 ± 0.62 , P-value=0.014, Figure 5), which was the same with the results of RNA-seq. In addition, a significantly negative association was observed between the expression level of *RHOC* and T staging of hepatic carcinoma with metastasis (Spearman coefficient $r = -0.949$, P-value=0.014).

Functional Network Analysis Of *RHOC* For Hepatic Carcinoma With Metastasis In PBMC Samples Based On Bio-Informatic Method

Frequency And Type Of *RHOC* Alterations In TCGA Database

Firstly, cBioPortal platform was used to describe the types and frequency of *RHOC* alterations in LIHC of TCGA database. As shown in Figure 6A, *RHOC* was altered in 24 of 377(6.4%) LIHC patients. These alterations were mRNA upregulation in 23 cases (6.1%) and mutation in 1 case (0.3%) (Table S3). Thus, the high expression is the




Figure 4 Overall survival for LIHC in TCGA (StarBase).

Notes: Cancer number was 369. Coefficient was 0.55. Hazard ratio was 1.73. Log-rank P-value was 0.0025.

most common type of *RHOC* alterations in LIHC, which altered in 12.5% of 8 hepatocellular carcinoma plus intra-hepatic cholangiocarcinoma and 5.13% of 22 hepatocellular carcinoma (Figure 6B). Besides, the expression level of *RHOC* was significantly negatively associated with gene methylation (Figure 6C), indicating that gene methylation alteration affected its gene expression level.

Biological Interaction Network Of RHOC With Its Neighboring Genes

Next, the tab Network in cBioPortal was used to identify *RHOC*-neighboring genes and determine the biological interaction network of them. When the alteration frequency was more than 20%, the neighbor gene was selected. The results were shown in Figure S1 and Table S3. *RHOC*-neighboring genes, including protein tyrosine kinase 2 gene (*PTK2*), phosphatidylinositol 4-phosphate 5-kinase type-1 alpha gene (*PIP5K1A*), Rho GTPase activating protein 39 gene

Table 2 The Baseline Characteristics Of The Samples That Were Used To Perform qRT-PCR

Samples	Sex	Age	Clinical TNM Staging
QG6	Female	70	T1N0M0
QG7	Male	66	T1N0M0
QG8	Female	72	T1N0M0
QG9	Female	75	T1N0M0
QG11	Male	69	T1N0M0
QG2	Male	71	T4N1M1
QG10	Female	74	T2N0M1
QG14	Male	70	T1N0M1
QG20	Male	70	T2N0M1
QG24	Female	64	T2N0M1




Figure 5 The differential expression of *RHOC* detected by qRT-PCR.

Notes: The hepatic carcinoma with metastasis 7.15 ± 0.88 vs hepatic carcinoma with solitary tumor 8.66 ± 0.62 , $P=0.014$. Data were represented as mean \pm standard deviation.

(*ARHGAP39*), and Rho guanine nucleotide exchange factor 11 gene (*ARHGEF11*), were selected and their biological interaction network was determined. All of them presented up-regulated alterations in LIHC. Among them, *PIP5K1A*, *ARHGAP39*, and *ARHGEF11* controlled the reaction that changed the state of *RHOC*. PANTHER GO-Slim and Pathway classification analysis showed that *PTK2* was the component of cell junction (GO: 0030054), and involved in biological adhesion (GO: 0022610), biological regulation (GO: 0065007), multicellular organismal process (GO: 0032501), angiogenesis (P00005), cholecystokinin receptor (CCKR) signaling map (P06959), Gonadotropin-releasing hormone receptor pathway (P06664), integrin signaling pathway (P00034), and VEGF signaling pathway (P00056); *PIP5K1A* and *ARHGAP39* were involved in catalytic activity (GO: 0003824); *ARHGAP39* was involved in molecular function regulator (GO: 0098772); *PTK2* and *PIP5K1A* were involved in metabolic process (GO: 0008152) and cellular process (GO: 0009987). However, none of *RHOC*-neighboring genes was found to be altered in our RNA-seq assay.

Biological Interaction Network Of RHOC With Its Co-Expression Genes

10,031 co-expression genes of *RHOC* were identified in LIHC of TCAG database by LinkedOmic platform, of which 232 genes were found to be altered in our RNA-seq assay. Through combination with the analysis performed by StarBase v3.0 platform, 15 co-expression genes were identified as the competing endogenous RNAs (ceRNAs) with *RHOC* and 4 co-expression genes presented RNA-RNA interactions with *RHOC*. The 15 co-expression genes were




Figure 6 *RHOC* alterations in TCGA LIHC (cBioPortal).

Notes: (A) The OncoPrint provided an overview of genomic alterations in *RHOC* affecting individual patients (columns) in LIHC from the TCGA. The different types of genetic alterations were highlighted in different colors. **RHOC* was altered in about 6% of LIHC patients. (B) *RHOC* alterations in different cancer types in LIHC of TCGA database. *RHOC* mRNA high altered in 12.5% of 8 hepatocellular carcinoma plus intrahepatic cholangiocarcinoma and 5.13% of 22 hepatocellular carcinoma. Mutation altered in 0.23% of 1 hepatocellular carcinoma. (C) The association between *RHOC* gene methylation and gene expression. P-value for Spearman test was $1.86E-7$; P-value for Pearson test was $1.359E-6$.

DDB1- and CUL4-associated factor 12 gene (*DCAF12*), peptidyl-prolyl cis-trans isomerase gene (*FKBP8*), sodium channel subunit beta-1 gene (*SCN1B*), forkhead box protein O3 gene (*FOXO3*), GAS2-like protein 1 gene (*GAS2L1*), tumor-specific transplantation antigen 3 gene (*TSTA3*), myosin regulatory light polypeptide 9 gene (*MYL9*), mitogen-activated protein kinase kinase 3 gene (*MAP2K3*), tensin-1 gene (*TNS1*), tetraspanin-9 gene (*TSPAN9*), EH domain-containing protein 3 gene (*EHD3*), activating signal cointegrator 1 complex subunit 2 gene (*ASCC2*), protein-glutamine gamma-glutamyltransferase 2 gene (*TGM2*), platelet endothelial aggregation receptor 1 gene (*PEAR1*), and Bcl-2-like protein 1 gene (*BCL2L1*). The 4 interactional genes with *RHOC* were glutathione peroxidase 1 gene (*GPX1*), *FKBP8*, transcription factor Dp-1 gene (*TFDP1*), and apolipoprotein L2 gene (*APOL2*). Their frequency and type of alterations and expression levels in LIHC of TCGA database were shown in [Table S4](#) and [Figure S2](#). And STRING v11.0

was used to present their biological interaction network ([Figure 7](#), [Tables 3](#) and [4](#)). The results showed that the interaction between *MYL9* and *RHOC* had the highest edge evidence (Score: 0.958), and through Reactome pathway enrichment analysis, they were found to be significantly involved in RHO GTPases activate ROCKs Pathway (HSA-5627117), RHO GTPases activate citron kinase (CIT) Pathway (HSA-5625900), RHO GTPases activate protein kinases Ns (PKNs) Pathway (HSA-5625740), and Sema4D induced cell migration and growth-cone collapse Pathway (HSA-416572) (False discovery rates (FDRs) were 0.0257, 0.0257, 0.0414, and 0.0257).

Discussion

Although there were some advances in hepatic carcinoma diagnosis and treatment, majority of the patients remains incurable with an unsatisfactory long-term prognosis, especially for hepatic carcinoma with metastasis.²⁻⁴




Figure 7 Biological interaction network of *RHOA* with its co-expression genes (STRING).

Notes: Number of nodes: 19; number of edges: 8; average node degree: 0.842; Avg. local clustering coefficient: 0.342; expected number of edges: 2; PPI enrichment P-value: 0.000516. The disconnected nodes were hidden. Thicker line indicated increased edge confidence. Nodes in green were involved in RHO GTPases activate ROCKs Pathway (HSA-5627117). Nodes in blue were involved in RHO GTPases activate CIT Pathway (HSA-5625900). Nodes in red were involved in Sema4D induced cell migration and growth-cone collapse Pathway (HSA-416572). Nodes in purple were involved in RHO GTPases activate PKNs Pathway (HSA-5625740). Nodes in yellow were involved in Intrinsic Pathway for Apoptosis (HSA-109606).

Existing clinical imaging diagnosis and serum markers lack adequate sensitivity and specificity for small metastasis or micro-metastasis, which lead to diagnostic delays or omissions to threaten people's life. Therefore, seeking effectively diagnostic and course monitoring biomarkers is still essential for hepatic carcinoma with metastasis.

Recently, increasing related studies have focused on this point. And it is generally accepted that transcellular migration of tumor cells through host structures is crucial in cancer invasion and metastasis. *RHOA* has been reported to play an important role in cell migration. It has attracted interest with its increased expression being linked to increased invasion, metastasis, and poor prognosis in various cancers, such as breast cancer, melanoma, pancreatic cancer, colon cancer, bladder cancer, non-small cell lung carcinoma, etc.^{20–22} Recently, *RHOA* has been also reported to be significantly involved in the invasion

and metastasis of hepatic carcinoma tissues.^{10–16} However, the hepatic carcinoma tissue which was used to evaluate *RHOA* expression level in majority of the studies was not seemed to be the ideal detection sample type for clinical course supervision. We downloaded the data from TCGA (Table S5). Spearman rank correlation test was performed, and the result showed that the expression level of *RHOA* was significantly associated with the tumor purity of the tissue samples (Spearman coefficient was -0.138 . P-value=0.011). It presented that the components of tumor tissue affected the expression level of *RHOA* and the heterogeneity of tumor tissues could cause inconsistencies among different studies. Thus, in this study, PBMC samples were used to identify the DEGs of hepatic carcinoma with metastasis, because it was not only being easily accessible and minimally invasive but also could benefit the reliability of the results.¹⁹ Our results of DEG screening assay by RNA-seq and validation assay by qRT-PCR showed that the expression level of *RHOA* in PBMCs was significantly higher in hepatic carcinoma with metastasis than in hepatic carcinoma with solitary tumor, which was consistent with previous studies.^{10–16} Overall survival analysis was performed in LIHC patients of TCGA database, indicating that up-regulated *RHOA* was significantly linked to the poor prognosis of hepatic carcinoma. Therefore, our results suggested that *RHOA* in PBMC samples could be a potentially minimally invasive biomarker for the diagnosis and clinical course supervision of hepatic carcinoma with metastasis.

In order to better understand the role of *RHOA* in hepatic carcinoma with metastasis, the multidimensionally functional and biological interaction network analysis was performed. Eighteen co-expression genes with *RHOA* were identified, including 15 ceRNAs and 4 interactional genes with *RHOA*. Among them, *TGM2* were reported to be dysregulated in hepatic carcinoma with metastasis by previous studies. Yamaguchi H et al presented that *TGM2* was upregulated in the early intrahepatic metastasis of hepatic carcinoma and might contribute to early hepatic carcinoma metastasis through signaling pathways unrelated to epithelial–mesenchymal transition (EMT) and integrin signaling.²³ PPI network was drawn to present the interactions between these co-expression genes and *RHOA*. Among them, the interaction between *MYL9* and *RHOA* had the highest edge evidence (Score: 0.958). *MYL9* was myosin regulatory subunit that played an important role in regulation of both smooth muscle and non-muscle cell contractile activity via its phosphorylation and implicated in cytoskeleton, receptor capping, and cell locomotion. Reactome

Table 3 The Interactions Of The Co-Expression Genes With *RHOC* For Hepatic Carcinoma With Metastasis In The Biological Network (STRING)

Node 1	Node 2	Node 1 Accession	Node 2 Accession	Score
<i>ASCC2</i>	<i>GAS2L1</i>	ENSP00000380877	ENSP00000481012	0.561
<i>BCL2L1</i>	<i>FKBP8</i>	ENSP00000302564	ENSP00000476767	0.654
<i>BCL2L1</i>	<i>FOXO3</i>	ENSP00000302564	ENSP00000385824	0.614
<i>BCL2L1</i>	<i>MAP2K3</i>	ENSP00000302564	ENSP00000345083	0.411
<i>BCL2L1</i>	<i>TNSI</i>	ENSP00000302564	ENSP00000171887	0.636
<i>FKBP8</i>	<i>BCL2L1</i>	ENSP00000476767	ENSP00000302564	0.654
<i>FOXO3</i>	<i>BCL2L1</i>	ENSP00000385824	ENSP00000302564	0.614
<i>FOXO3</i>	<i>TNSI</i>	ENSP00000385824	ENSP00000171887	0.664
<i>GAS2L1</i>	<i>ASCC2</i>	ENSP00000481012	ENSP00000380877	0.561
<i>MAP2K3</i>	<i>BCL2L1</i>	ENSP00000345083	ENSP00000302564	0.411
<i>MYL9</i>	<i>RHOC</i>	ENSP00000279022	ENSP00000285735	0.958
<i>RHOC</i>	<i>MYL9</i>	ENSP00000285735	ENSP00000279022	0.958
<i>RHOC</i>	<i>TNSI</i>	ENSP00000285735	ENSP00000171887	0.446
<i>TNSI</i>	<i>BCL2L1</i>	ENSP00000171887	ENSP00000302564	0.636
<i>TNSI</i>	<i>FOXO3</i>	ENSP00000171887	ENSP00000385824	0.664
<i>TNSI</i>	<i>RHOC</i>	ENSP00000171887	ENSP00000285735	0.446

Table 4 The Reactome Pathways Enrichments In The Biological Network Of The Co-Expression Genes With *RHOC* For Hepatic Carcinoma With Metastasis

Pathway	Description	Count In Gene Set	FDR
HSA-5627117	RHO GTPases Activate ROCKs	2 of 19 (<i>MYL9</i> and <i>RHOC</i>)	0.0257
HSA-5625900	RHO GTPases activate CIT	2 of 19 (<i>MYL9</i> and <i>RHOC</i>)	0.0257
HSA-416572	Sema4D induced cell migration and growth-cone collapse	2 of 20 (<i>MYL9</i> and <i>RHOC</i>)	0.0257
HSA-109606	Intrinsic Pathway for Apoptosis	2 of 43 (<i>BCL2L1</i> and <i>TFDP1</i>)	0.0257
HSA-5625740	RHO GTPases activate PKNs	2 of 63 (<i>MYL9</i> and <i>RHOC</i>)	0.0414

pathway enrichment analysis showed that *MYL9* and *RHOC* were significantly involved in RHO GTPases activate ROCKs Pathway (HSA-5627117), RHO GTPases activate CIT Pathway (HSA-5625900), RHO GTPases activate PKNs Pathway (HSA-5625740), and Sema4D induced cell migration and growth-cone collapse Pathway (HSA-416572). The interactional network of these pathways is shown in Figure 8. RHO GTPases activate ROCKs Pathway (HSA-5627117) which was reported to play an important role in the hepatic carcinoma with metastasis was involved in Sema4D induced cell migration and growth-cone collapse Pathway (HSA-416572). Sema4D-mediated plexinB1 activation activated RHOA/RHOB/RHOC and its downstream effector ROCK.²⁴⁻²⁷ ROCK then phosphorylated myosin regulatory light chains (MRLC), including *MYL9* and *MYL12B*, to induce actomyosin stress fiber contraction and to direct the assembly of focal adhesion complexes and integrin-mediated adhesion.²⁶⁻³⁰ The phosphorylation of MRLC also could be promoted by RHO GTPases activate PKNs Pathway

(HSA-5625740) and RHO GTPases activate CIT Pathway (HSA-5625900). RHO GTPases RHOA, RHOB, RHOC and Ras-related C3 botulinum toxin substrate 1 (*RAC1*) bound to *PKN1*, *PKN2*, and *PKN3*, bringing them in proximity to the PIP3-activated co-activator 3-phosphoinositide-dependent protein kinase 1 (*PDPK1*).^{31,32} *PDPK1* phosphorylated *PKNs* on a highly conserved threonine residue in the kinase activation loop.^{31,32} Activated *PKN1* (p-T774-*PKN1*) phosphorylated protein phosphatase 1 regulatory subunit 14A (*PPP1R14A*), which could subsequently phosphorylate on threonine T38 binds *MLCP* (myosin light chain phosphatase complex) and inhibit its catalytic activity to increase *MRLC* phosphorylation.³³⁻³⁸ RHO GTPases RHOA, RHOB, RHOC, and *RAC1* also could bind to *CIT*, which might be activated through autophosphorylation to phosphorylate the *MRLC*.^{39,40}

Conclusion

To our knowledge, this study first presented that *RHOC* in PBMCs could be a potentially minimally invasive biomarker

kinase; PKNs, protein kinases Ns; FDR, false discovery rate; EMT, epithelial–mesenchymal transition; MRLC, myosin regulatory light chains; RAC1, Ras-related C3 botulinum toxin substrate 1; PDPK1, PIP3-activated co-activator 3-phosphoinositide-dependent protein kinase 1; PPP1R14A, protein phosphatase 1 regulatory subunit 14A; RBPs, RNA-binding proteins; CLIP, cross-linking immunoprecipitation.

Availability Of Data

RNA-seq data were stored in the NCBI Short Read Archive (SRP094502).

Acknowledgment

This study was supported by the National Natural Science Foundation of China (grant number 61271055).

Disclosure

The authors report no conflicts of interest in this work.

References

- Gao C. Molecular pathological epidemiology: an interdisciplinary field for study of hepatocellular carcinoma. *Austin J Gastroenterol*. 2015;2:1040.
- Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. *Gastroenterology*. 2002;122:1609–1619.
- Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. *Cancer Cell*. 2006;1099–1111.
- Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. *World J Hepatol*. 2015;7:1632–1651.
- Okuda K. Hepatocellular carcinoma: clinicopathological aspects. *J Gastroenterol Hepatol*. 1997;12:S314–318.
- Salvador E, Burek M, Förster CY. Tight junctions and the tumor microenvironment. *Curr Pathobiol Rep*. 2016;4:135–145. doi:10.1007/s40139-016-0106-6
- Yamaguchi H, Wyckoff J, Condeelis J. Cell migration in tumors. *Curr Opin Cell Biol*. 2005;17:559–564. doi:10.1016/j.ceb.2005.08.002
- Yamazaki D, Kurisu S, Takenawa T. Regulation of cancer cell motility through actin reorganization. *Cancer Sci*. 2005;96:379–386. doi:10.1111/j.1349-7006.2005.00062.x
- Burridge K, Wennerberg K. Rho and Rac take center stage. *Cell*. 2004;116:167–179. doi:10.1016/s0092-8674(04)00003-0
- Wang W, Yang LY, Yang ZL, Huang GW, Lu WQ. Expression and significance of RhoC gene in hepatocellular carcinoma. *World J Gastroenterol*. 2003;9:1950–1953. doi:10.3748/wjg.v9.i9.1950
- Wang W, Yang LY, Huang GW, et al. Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. *Br J Cancer*. 2004;90:2349–2355. doi:10.1038/sj.bjc.6601749
- Yang LY, Wang W, Peng JX, Yang JQ, Huang GW. Differentially expressed genes between solitary large hepatocellular carcinoma and nodular hepatocellular carcinoma. *World J Gastroenterol*. 2004;10:3569–3573. doi:10.3748/wjg.v10.i24.3569
- Mukai M, Endo H, Iwasaki T, et al. RhoC is essential for TGF-beta1-induced invasive capacity of rat ascites hepatoma cells. *Biochem Biophys Res Commun*. 2006;346:74–82. doi:10.1016/j.bbrc.2006.05.068
- Wang W, Yang LY, Yang ZL, Peng JX, Yang JQ. Elevated expression of autocrine motility factor receptor correlates with overexpression of RhoC and indicates poor prognosis in hepatocellular carcinoma. *Dig Dis Sci*. 2007;52:770–775. doi:10.1007/s10620-006-9479-4
- Wang W, Peng JX, Yang JQ, Yang LY. Identification of gene expression profiling in hepatocellular carcinoma using cDNA microarrays. *Dig Dis Sci*. 2009;54:2729–2735. doi:10.1007/s10620-008-0667-2
- Xie S, Zhu M, Lv G, et al. Overexpression of Ras homologous C (RhoC) induces malignant transformation of hepatocytes in vitro and in nude mouse xenografts. *PLoS ONE*. 2013;8:e54493. doi:10.1371/journal.pone.0054493
- Croft DR, Sahai E, Mavria G, et al. Conditional ROCK activation in vivo induces tumor cell dissemination and angiogenesis. *Cancer Res*. 2004;64:8994–9001. doi:10.1158/0008-5472.CAN-04-2052
- Wang W, Wu F, Fang F, Tao Y, Yang L. RhoC is essential for angiogenesis induced by hepatocellular carcinoma cells via regulation of endothelial cell organization. *Cancer Sci*. 2008;99:2012–2018. doi:10.1111/j.1349-7006.2008.00902.x
- Shen Y, Bu L, Li R, et al. Screening effective differential expression genes for hepatic carcinoma with metastasis in the peripheral blood mononuclear cells by RNA-seq. *Oncotarget*. 2017;8:27976–27989. doi:10.18632/oncotarget.15855
- Karlsson R, Pedersen ED, Wang Z, Brakebusch C. Rho GTPase function in tumorigenesis. *Biochim Biophys Acta*. 2009;1796:91–98. doi:10.1016/j.bbcan.2009.03.003
- Baranwal S, Alahari SK. Rho GTPase effector functions in tumor cell invasion and metastasis. *Curr Drug Targets*. 2011;12:1194–1201. doi:10.2174/138945011795906534
- Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. *FEBS Lett*. 2008;582:2093–2101. doi:10.1016/j.febslet.2008.04.039
- Yamaguchi H, Kuroda K, Sugitani M, Takayama T, Hasegawa K, Esumi M. Transglutaminase 2 is upregulated in primary hepatocellular carcinoma with early recurrence as determined by proteomic profiles. *Int J Oncol*. 2017;50:1749–1759. doi:10.3892/ijo.2017.3917
- Zhou Y, Gunput RA, Pasterkamp RJ. Semaphorin signaling: progress made and promises ahead. *Trends Biochem Sci*. 2008;33:161–170. doi:10.1016/j.tibs.2008.01.006
- Hirotni M, Ohoka Y, Yamamoto T, et al. Interaction of plexin-B1 with PDZ domain-containing Rho guanine nucleotide exchange factors. *Biochem Biophys Res Commun*. 2002;297:32–37. doi:10.1016/s0006-291x(02)02122-8
- Swiercz JM, Kuner R, Offermanns S. Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor tyrosine kinase ErbB-2. *J Cell Biol*. 2004;165:869–880. doi:10.1083/jcb.200312094
- Negishi M, Oinuma I, Katoh H. Plexins: axon guidance and signal transduction. *Cell Mol Life Sci*. 2005;62:1363–1371. doi:10.1007/s00018-005-5018-2
- Amano M, Ito M, Kimura K, et al. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). *J Biol Chem*. 1996;271:20246–20249. doi:10.1074/jbc.271.34.20246
- Watanabe T, Hosoya H, Yonemura S. Regulation of myosin II dynamics by phosphorylation and dephosphorylation of its light chain in epithelial cells. *Mol Biol Cell*. 2007;18:605–616. doi:10.1091/mbc.e06-07-0590
- Ueda K, Murata-Hori M, Tatsuka M, Hosoya H. Rho-kinase contributes to diphosphorylation of myosin II regulatory light chain in nonmuscle cells. *Oncogene*. 2002;21:5852–5860. doi:10.1038/sj.onc.1205747
- Flynn P, Mellor H, Casamassima A, Parker PJ. Rho GTPase control of protein kinase C-related protein kinase activation by 3-phosphoinositide-dependent protein kinase. *J Biol Chem*. 2000;275:11064–11070. doi:10.1074/jbc.275.15.11064
- Torbett NE, Casamassima A, Parker PJ. Hyperosmotic-induced protein kinase N1 activation in a vesicular compartment is dependent upon Rac1 and 3-phosphoinositide-dependent kinase. *J Biol Chem*. 2003;278:32344–32351. doi:10.1074/jbc.M303532200

33. Hamaguchi T, Ito M, Feng J, et al. Phosphorylation of CPI-17, an inhibitor of myosin phosphatase, by protein kinase N. *Biochem Biophys Res Commun.* 2000;274:825–830. doi:10.1006/bbrc.2000.3225
34. Eto M, Kitazawa T, Brautigan DL. Phosphoprotein inhibitor CPI-17 specificity depends on allosteric regulation of protein phosphatase-1 by regulatory subunits. *Proc Natl Acad Sci.* 2004;101:8888–8893. doi:10.1073/pnas.0307812101
35. Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). *Science.* 1996;273:245–248. doi:10.1126/science.273.5272.245
36. Katoh K, Kano Y, Amano M, Onishi H, Kaibuchi K, Fujiwara K. Rho-kinase-mediated contraction of isolated stress fibers. *J Cell Biol.* 2001;153:569–584. doi:10.1083/jcb.153.3.569
37. Iwasaki T, Murata-Hori M, Ishitobi S, Hosoya H. Diphosphorylated MRLC is required for organization of stress fibers in interphase cells and the contractile ring in dividing cells. *Cell Struct Funct.* 2001;26:677–683. doi:10.1247/csf.26.677
38. Nakai K, Suzuki Y, Kihira H, et al. Regulation of myosin phosphatase through phosphorylation of the myosin-binding subunit in platelet activation. *Blood.* 1997;90:936–942.
39. Madaule P, Furuyashiki T, Reid T, et al. A novel partner for the GTPbound forms of rho and rac. *FEBS Lett.* 1995;377:243–248. doi:10.1016/0014-5793(95)01351-2
40. Di Cunto F, Calautti E, Hsiao J, et al. Citron rho-interacting kinase, a novel tissue-specific ser/thr kinase encompassing the Rho-Rac-binding protein Citron. *J Biol Chem.* 1998;273:29706–29711. doi:10.1074/jbc.273.45.29706
41. Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y. RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. *Genome Res.* 2008;18:1509–1517. doi:10.1101/gr.079558.108
42. Mi H, Muruganujan A, Casagrande JT, Thomas PD. Large-scale gene function analysis with the PANTHER classification system. *Nat Protoc.* 2013;8:1551–1566. doi:10.1038/nprot.2013.092
43. Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res.* 2019;47:D607–D613. doi:10.1093/nar/gky1131
44. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal.* 2013;6:pl1.
45. Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. *Nucleic Acids Res.* 2018;46:D956–D963. doi:10.1093/nar/gkx1090
46. Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase: decoding the atlas of miRNA-target, RNA-RNA and protein-RNA interactions networks from large-scale CLIP-Seq data. *Nucleic Acids Res.* 2014;42:D92–D97. doi:10.1093/nar/gkt1248
47. Yang JH, Li JH, Shao P, Zhou H, Chen YQ, Qu LH. starBase: a database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data. *Nucleic Acids Res.* 2011;39:D202–D209. doi:10.1093/nar/gkq1056

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>